159 related articles for article (PubMed ID: 26516615)
1. Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
McGurgan IJ; McGuigan C
Brain Behav; 2015 Oct; 5(10):e00396. PubMed ID: 26516615
[TBL] [Abstract][Full Text] [Related]
2. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2014 Mar; 21(3):454-8. PubMed ID: 24330255
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study.
Narayanaswami P; Sanders DB; Thomas L; Thibault D; Blevins J; Desai R; Krueger A; Bibeau K; Liu B; Guptill JT;
Lancet Neurol; 2024 Mar; 23(3):267-276. PubMed ID: 38365379
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
Rawoot A; Little F; Heckmann JM
S Afr Med J; 2006 Dec; 96(12):1249-51. PubMed ID: 17252153
[No Abstract] [Full Text] [Related]
5. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis.
Zhang Z; Wang M; Xu L; Jiang B; Jin T; Shi T; Xu B
J Clin Neurosci; 2021 Jun; 88():70-74. PubMed ID: 33992207
[TBL] [Abstract][Full Text] [Related]
6. [Eruptive melanocytic nevi during azathioprine therapy in myasthenia gravis].
Braun SA; Helbig D; Frank J; Hanneken S
Hautarzt; 2012 Oct; 63(10):756-9. PubMed ID: 23008007
[TBL] [Abstract][Full Text] [Related]
7. Risk of nonmelanoma skin cancer with azathioprine use.
Maddox JS; Soltani K
Inflamm Bowel Dis; 2008 Oct; 14(10):1425-31. PubMed ID: 18383175
[TBL] [Abstract][Full Text] [Related]
8. A review of heart transplant immunosuppressants and nonmelanoma skin cancer.
Eckembrecher DG; Eckembrecher FJ; Camacho I; Shah H; Dave Y; Patel S; Nouri K
Arch Dermatol Res; 2023 Nov; 315(9):2491-2503. PubMed ID: 37256379
[TBL] [Abstract][Full Text] [Related]
9. [Myasthenia gravis. Opportunistic cytomegalovirus infection after long-term azathioprine therapy].
Eisensehr I; Büttner U; Witt TN; von Appen K; Spuler S
Nervenarzt; 1999 Oct; 70(10):924-6. PubMed ID: 10554786
[TBL] [Abstract][Full Text] [Related]
10. Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases.
van den Reek JM; van Lümig PP; Janssen M; Schers HJ; Hendriks JC; van de Kerkhof PC; Seyger MM; de Jong EM
J Eur Acad Dermatol Venereol; 2014 Jan; 28(1):27-33. PubMed ID: 23216663
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.
Hohlfeld R; Michels M; Heininger K; Besinger U; Toyka KV
Neurology; 1988 Feb; 38(2):258-61. PubMed ID: 3340289
[TBL] [Abstract][Full Text] [Related]
12. Low-dose azathioprine effectively suppresses clinical and immunological manifestations of generalized myasthenia.
Finsterer J; Frank M; Krexner E
South Med J; 2010 Feb; 103(2):182-4. PubMed ID: 20065912
[No Abstract] [Full Text] [Related]
13. [Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital].
Rodríguez-Acosta ED; Calva-Mercado JJ; Alberú-Gómez J; Vilatoba-Chapa M; Domínguez-Cherit J
Gac Med Mex; 2015; 151(1):20-6. PubMed ID: 25739480
[TBL] [Abstract][Full Text] [Related]
14. Visceral leishmaniasis masquerading as drug-induced pancytopenia in myasthenia gravis.
Nath UK; Bhattacharyya D; Chattopadhya D; Dhingra G; Azad S; Mohanty A
Drug Discov Ther; 2021 Mar; 15(1):48-50. PubMed ID: 33612571
[TBL] [Abstract][Full Text] [Related]
15. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
16. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark.
Pedersen EG; Pottegård A; Hallas J; Friis S; Hansen K; Jensen PE; Gaist D
Eur J Neurol; 2013 Jun; 20(6):942-8. PubMed ID: 23448676
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognosis of myasthenia gravis in older people.
Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis.
Dodd KC; Ahmed R; Ambrose P; Holt JK; Jacob S; Leite MI; Miller JA; San PP; Spillane J; Viegas S; Sussman J
Neuromuscul Disord; 2024 May; 38():51-57. PubMed ID: 38626662
[TBL] [Abstract][Full Text] [Related]
19. [Myasthenic crisis caused by azathioprine-induced fever].
Tumani H; George A; Nau R
Nervenarzt; 1997 Apr; 68(4):336-8. PubMed ID: 9273463
[TBL] [Abstract][Full Text] [Related]
20. Long-term, low-dose immunosuppression for myasthenia does not affect collateral, asymptomatic sclerosing cholangitis.
Finsterer J; Höflich S
Arq Neuropsiquiatr; 2012 Feb; 70(2):158-9. PubMed ID: 22311226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
